男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
English 中文網 漫畫網 愛新聞iNews 翻譯論壇
中國網站品牌欄目(頻道)
當前位置: Language Tips > Normal Speed News VOA常速

Scientists seek HIV vaccine using monkey model

[ 2012-09-18 10:57] 來源:中國日報網     字號 [] [] []  
免費訂閱30天China Daily雙語新聞手機報:移動用戶編輯短信CD至106580009009

Get Flash Player

Download

Traditional vaccine methods have been unsuccessful in preventing infection by HIV, the virus that causes AIDS. New techniques are being studied to boost antibodies or other parts of the immune system. But researchers are also working on a method to keep the immune system constantly on guard against HIV.

There are two traditional methods for creating a vaccine. One uses a weakened or attenuated version of a live virus to generate an immune response. The other uses a dead virus. Both methods are proven safe and effective, except when it comes to HIV. Vaccine candidates using these methods simply have not been successful in people when it comes to the AIDS virus.

“HIV has been a very difficult target for a vaccine for a variety of reasons. It’s designed to evade the immune response by evolution,” said Dr. Louis Picker, associate director of Oregon Health and Science University.

While attempts to make an HIV vaccine from a dead virus have failed, Picker said, using a weakened virus holds clues and possibilities when used in primates.

“The live attenuated approach actually was shown to work 20 years ago. But the problem with it was the live attenuated vaccines that actually worked were actually still pathogenic. So they weren’t safe and they could not be moved into humans. This was demonstrated in the non-human primate models – monkey model of AIDS using the virus SIV,” he said.

SIV stands for simian immunodeficiency virus.

“These SIVs that were attenuated, that prevented subsequent infection with the full pathogenic virus, still could cause disease. And people found that if you attenuated them anymore, they didn’t work anymore,” he said.

Picker and his colleagues wanted to understand why the weakened virus offered protection from infection. But at the same time, they needed to prevent it from itself causing disease. They found the answer has to do with T cells, which attack viruses. The weakened, but persistent virus vaccines somehow caused T cells to be ever vigilant. But if the virus was weakened too much, the T cells were not triggered to attack. They concluded that an “effective HIV vaccine might have to persist in the body.”

Picker said, “The unique aspect of the live attenuated vaccines that seem to work was that they were persistent. They weren’t cleared by the host immune system, but they were able to stick around. Of course in the case of HIV/SIV that’s a bad thing, because eventually those live attenuated vaccines would gain strength and cause disease. But probably the fundamental reason, at least what I hypothesized, that they would be able to elicit protection was because of that persistence.”

So, they looked for another persistent virus that was not pathogenic, which might generate T cell immune response.

“The virus that we selected was a virus called cytomegalovirus (CMV), which is actually a virus from a different family of viruses altogether, but it’s one that most people in the world are infected with. But it’s unique in that you can re-infect these people with a virus that now has within its genes HIV genes and then the body would make immune responses to those HIV genes,” he said.

The HIV genes that would be placed in the harmless virus, he said, would not cause disease.

“When they’re introduced into the vaccinee, the immune response recognizes these HIV bits as if they’re part of CMV and raises immune response to it,” he said.

That’s the plan, anyway. The difficult part is making a version of the vaccine that’s safe and effective for humans. That requires an approved vaccine candidate and years of clinical trials.

Meanwhile, in Thailand, a follow-up study is getting underway of the RV 144 vaccine candidate. Several years ago, a study showed that it did indeed provide some measure of protection against HIV, but not enough, being only 31 percent effective. A clinical study called RV 305 will use the same vaccine components as RV 144, but will attempt to boost and extend the immune response through antibodies.

相關閱讀

Tensions rising again over Iran's nuclear program(視頻)

Mideast protests spark debate over free speech, religion(視頻)

The Occupy Movement turns one

American's first exchange students from China

(來源:VOA 編輯:Julie)

 
中國日報網英語點津版權說明:凡注明來源為“中國日報網英語點津:XXX(署名)”的原創作品,除與中國日報網簽署英語點津內容授權協議的網站外,其他任何網站或單位未經允許不得非法盜鏈、轉載和使用,違者必究。如需使用,請與010-84883631聯系;凡本網注明“來源:XXX(非英語點津)”的作品,均轉載自其它媒體,目的在于傳播更多信息,其他媒體如需轉載,請與稿件來源方聯系,如產生任何問題與本網無關;本網所發布的歌曲、電影片段,版權歸原作者所有,僅供學習與研究,如果侵權,請提供版權證明,以便盡快刪除。
 

關注和訂閱

人氣排行

翻譯服務

中國日報網翻譯工作室

我們提供:媒體、文化、財經法律等專業領域的中英互譯服務
電話:010-84883468
郵件:translate@chinadaily.com.cn
 
 
主站蜘蛛池模板: 安丘市| 西丰县| 盐边县| 上蔡县| 集安市| 弋阳县| 互助| 德阳市| 沙洋县| 阿拉善盟| 沿河| 防城港市| 沁源县| 密云县| 高青县| 南部县| 德格县| 建始县| 同仁县| 麻江县| 海阳市| 张北县| 开远市| 五原县| 梧州市| 钦州市| 北海市| 泰顺县| 祁门县| 石首市| 米易县| 苏尼特右旗| 台南县| 施甸县| 清远市| 黄陵县| 温州市| 中江县| 石楼县| 桂林市| 丹东市| 和政县| 巴林左旗| 伊吾县| 德安县| 东阳市| 建水县| 射洪县| 衡水市| 黄石市| 绍兴县| 进贤县| 凤山市| 库尔勒市| 宁南县| 井冈山市| 达尔| 镇赉县| 陇南市| 霍林郭勒市| 旬邑县| 大名县| 禹城市| 武定县| 兴业县| 彝良县| 台山市| 双流县| 镇宁| 临沂市| 鄢陵县| 依兰县| 灯塔市| 台南市| 胶南市| 工布江达县| 大冶市| 手游| 静安区| 永济市| 海伦市| 隆德县|